Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Chronic Myelogenous Leukaemia

This page shows the latest Chronic Myelogenous Leukaemia news and features for those working in and with pharma, biotech and healthcare.

Merck to acquire Imago BioSciences in deal worth $1.35bn

Merck to acquire Imago BioSciences in deal worth $1.35bn

Additionally, certain MPNs may become acute myeloid leukaemia. MPNs include chronic myelogenous leukaemia (CML), polycythaemia vera (PV), primary myelofibrosis (MF), essential thrombocythaemia (ET), chronic neutrophilic leukaemia and chronic

Latest news

  • Pfizer’s leukaemia drug Mylotarg backed for use in EU Pfizer’s leukaemia drug Mylotarg backed for use in EU

    The FDA approved the drug last September. “There is an urgent need to improve outcomes for leukaemia patients in Europe,” said Pfizer’s chief development officer Mace Rothenberg. ... Kineret (anakinra) in rare inflammatory condition Still’s

  • Novartis pulls EMA application for expanded Tasigna use Novartis pulls EMA application for expanded Tasigna use

    The company said it no longer wishes to seek approval for its cancer treatment Tasigna (nilotinib) in patients with Philadelphia-chromosome-positive chronic myelogenous leukaemia (CML) who did not achieve 'complete ... Tasigna is already approved in the

  • Novartis' Tasigna tops Glivec in long-term trial Novartis' Tasigna tops Glivec in long-term trial

    Boost ahead of patent expiry for leukaemia drug. New phase III data has revealed that Novartis' chronic myelogenous leukaemia (CML) treatment Tasigna is more effective than forerunner Glivec over the

  • Scotland first in UK to back Pfizer's Inlyta Scotland first in UK to back Pfizer's Inlyta

    The Scottish agency concurred with earlier NICE guidance however and did not support the use of Pfizer's Bosulif (bosutinib) as a back-up treatment for chronic phase, accelerated phase, and ... blast phase Philadelphia chromosome-positive chronic

  • Roche wins conditional EU approval for cancer drug Erivedge Roche wins conditional EU approval for cancer drug Erivedge

    Other drugs to receive conditional approval in Europe in recent years include GlaxoSmithKline's (GSK) renal cell carcinoma treatment Votrient (pazopanib), Pfizer's chronic myelogenous leukaemia (CML) treatment Bosulif (bosutinib) and

More from news
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Therapy Watch expands oncology and IBD portfolios

    This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in the ... Therapy Watch CML is part of a wider oncology

  • Research Partnership Research Partnership

    Prescription medicines. Within prescription medicines, we have therapeutic specialists and experience in a broad range of therapy areas from chronic illnesses to rare diseases. ... new Chronic Myelogenous Leukaemia (CML) study in the US.

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Mednet Group

PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...

Latest intelligence

New Playbook Alert: Virtual Patient Engagement
...
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....

Quick links